2025 CES文章顶部

Chinese Brain-computer Interface Startup NeuroXess Completes Series A Financing

BCI technologies that could be used to treat patients with blindness, high paraplegia or amyotrophic lateral sclerosis received another round of financing.

The brain-computer interface device developed by NeuroXess debuted at WAIC 2022 with a monkey model. (Source: TMTPost)

The brain-computer interface device developed by NeuroXess debuted at WAIC 2022 with a monkey model. (Source: TMTPost)

By Lin Zhijia and Shaw Wan

BEIJING, December 28 (TMTPOST) — NeuroXess, a Shanghai-based high-tech life science company, raised hundreds of millions of yuan, or tens of millions of dollars, in its series A round on Wednesday.

The latest fundraising round was led by Zhongping Capital, a Shanghai-based private equity firm. Previous investors Shanda, Lianxin Capital and Sequoia Capital China continued to invest. Other participants included LightSilver Capital, Guosheng Capital, Sailing Capital and Yanhuaboyi.

NeuroXess provides brain-computer interface (BCI) technologies to protect and explore the brain. It developed China’s first semi-invasive BCI medical device that targets markets of human brain research and treating neurological diseases.

Wu Bin, founder and chief executive officer of Zhongping Capital, said that brain-computer interface technology is a brand new path for humans to further explore the brain and develop new therapeutic technology platforms. “It is full of unknowns and challenges, and the world is at a critical stage of development.”

“Congratulations to NeuroXess for completing a new round of financing. I am very happy to see that this Chinese invasive BCI technology research and development enterprise has made steady progress in human clinical trials and has continuously achieved results. Interestingly, Synchron, an American BCI company invested by Shanda, raised  75 million dollars last week. New investors included funds from Bezos and Bill Gates,” said Chen Tianqiao, founder of Shanda and the BCI research center Tianqiao and Chrissy Chen Institute (TCCI).

The Chinese BCI developer NeuroXess was founded in November 2021. It claims to be the Chinese version of Neuralink, a BCI firm established by Elon Musk, who is also the chief executive officer of spacecraft maker SpaceX, electric car provider Tesla and the social media platform Twitter.

In January, the company managed to raise 97 million yuan ($15.2 million) in the angel round and the pre-Series A round, led by Shanda Group and Sequoia Capital.

转载请注明出处、作者和本文链接
声明:文章内容仅供参考、交流、学习、不构成投资建议。
想和千万钛媒体用户分享你的新奇观点和发现,点击这里投稿 。创业或融资寻求报道,点击这里

敬原创,有钛度,得赞赏

赞赏支持
发表评论
0 / 300

根据《网络安全法》实名制要求,请绑定手机号后发表评论

登录后输入评论内容

快报

更多

18:07

12306系统售票高峰运行正常,1月11日拒绝异常登录请求3982万次

18:06

罗氏制药:玛巴洛沙韦在中国未发现耐药情况

17:27

中信、新湖、融创三家合作开发的“上海壹号院”开盘销售额达66亿元

17:08

中国宝武向西藏日喀则市定日县地震灾区捐赠1200万元

17:07

凯尔特亚洲合伙人Sky Yu:旺季是跨境物流的试金石,一旦失误就一落千丈

16:57

40万吨级超大型“海上油气工厂”上部模块完工交付

16:43

新人工智能模型可精确预测人体细胞基因表达

16:33

全国公安机关去年立案侦办环食药和知识产权领域刑事案件9.1万起

16:32

一汽解放:2024年货车及客车合计销量为25.11万辆,同比增长3.9%

16:31

上海莱士:控股股东增持公司股份取得专项贷款承诺函

16:30

聚灿光电:年产240万片红黄光外延片、芯片项目已投产

16:29

飞龙股份:内外部经营环境未发生重大变化

16:28

巨轮智能:机器人相关业务收入对公司短期业绩影响有限

16:05

三花智控:不存在应披露而未披露的重大事项

16:00

深南电路:2024年前三季度光模块产品等需求在AI带动下有所增长

15:59

回乡300多元“住高星”,县城豪华酒店预订量翻番

15:58

*ST信通:公司股票被叠加实施退市风险警示

15:57

磷酸奥司他韦进口和国产有何区别?工信部详解

15:49

专家:抗流感药物是处方药,不建议自己使用

15:38

6连板粤宏远A:可能存在短期涨幅较大后下跌的风险

扫描下载App

Baidu
map